Researchers at Kyoto University have made significant progress in understanding Down syndrome by focusing on the protein kinase DYRK1A. Their findings provide new insights into the molecular mechanisms of Down syndrome and autism spectrum disorders, as well as potential clinical applications in treating these disorders.
A recent study identified a role for FAM53C in regulating DYRK1A, providing new insights into the cellular mechanisms and potential clinical implications of Down syndrome.
Down syndrome is a congenital disorder caused by abnormalities in cell division and differentiation that most commonly affects newborns with neurodevelopmental delays and other health complications.
This genetic defect leads to dysfunction of the protein kinase DYRK1A, which is encoded on chromosome 21 and is closely linked to Down syndrome and autism spectrum disorders. DYRK1A has attracted much attention as a target molecule for the treatment of various diseases, but the specific cellular mechanism that regulates DYRK1A enzyme has not yet been clarified.
Now, researchers at Kyoto University have identified the FAM53C protein and its inhibitory effect on DYRK1A, which renders the protein kinase inactive in the cytoplasm.
"Our findings demonstrate the important role of the intracellular regulatory mechanism of DYRK1A in the normal development and function of the neuropsychiatric system," said first author Yoshihiko Miyata, Graduate School of Biology, Kyoto University. "I am fascinated by the highly complex molecular regulation of development and activity of the human brain. In addition to neuropsychiatric symptoms, Down syndrome may lead to Alzheimer's disease, type 2 diabetes, and facial dysplasia. Given the importance of DYRK1A, we explored potential molecules that serve as its interacting counterparts."
DYRK1A controls many biological functions, including nervous system development and function. At the cellular level, this key protein phosphorylates various other proteins in the cytoplasm and nucleus, thereby regulating the cell cycle, cell differentiation, cytoskeleton formation, and DNA damage response.
After identifying DCAF7/WDR68 as the primary binding protein of DYRK1A in previous studies, Miyata's research group used mass spectrometry to discover other interacting proteins that regulate DYRK1A function and cellular location. Notably, the structurally flexible FAM53C protein directly binds to the region of DYRK1A responsible for protein phosphorylation. This interaction reduces the kinase activity of DYRK1A, allowing DYRK1A to become anchored in the cytoplasm and outside the nucleus, as in normal brain tissue.
"FAM53C-mediated regulation of protein kinase activity may have a significant impact on the regulation of gene expression caused by normal and abnormal levels of DYRK1A, giving us many potential clinical implications," Miyata said.
Compiled source: ScitechDaily